Standardized plant material for drug development.
Multi target/multi component approach.
.jpg)
Treat and manage disease with little to no side effects.
Our vision is to transform cancer treatment into disease management. We do not accept that unwanted side effects are an inevitable part of efficacious treatment. Nor do we accept that remission period should be brief.
RH324 acts in a pleiotropic manner. The multifaceted and broad spectrum benefits of RH324 allow it to have a positive effect on a multitude of pathways involved in cancer, as well as on specific targets within those pathways.
Through rigorous clinical trials, we hope to demonstrate the synergy between our drug candidate, RH324, and anti-cancer drugs — including chemotherapy, targeted agents, and immunotherapy.
Founded in 2016, ReHeva Biosciences is a clinical-stage, biopharmaceutical company focused on discovering and developing naturally occurring complex drugs.
Our goal is to develop naturally occurring complex botanicals to improve and extend the lives of cancer patients while treating and managing the disease. At ReHeva, we use botanicals as the starting point for our cancer drug development. Then, we improve upon those and bring new, 100% natural drugs to market that are effective at treating and managing cancer.
ReHeva highlights the importance of returning the body to a healthy and improved state during and following cancer treatment, for a long period of time. We are addressing both an unmet need and an opportunity to develop safe and effective cancer drugs.
We are now initiating the FDA’s Phase 1 Safety Trial and planning for Phase 2 Efficacy Trials. Conducted over the next several years, Phase 2 trials will cover more than one cancer indication.
Our international research team was involved in pre-clinical drug discovery and development.
The FDA allowed our Investigational New Drug Application (IND), to conduct a Phase 1 Safety Study in advanced non-small cell lung cancer patients.
We conducted drug improvement, non-clinical safety studies, new analytical and assay development, cGMP manufacturing process development, and Controlled Environment Agriculture studies.
IND amendment to include revised drug formulation.
Phase I Safety Trial began in advanced non-small cell lung cancer patients at University Hospitals in Cleveland.
RHV18002 - Phase 1 Open label dose-ranging study of twice daily oral RH324 (500mg/cap) in adults with advanced non-small cell lung cancer.
We believe that science is bigger than any one person. Therefore, we’ve come together from different countries and continents to work as one team. At ReHeva, we are all empowered to think differently, push scientific boundaries, challenge the status quo, and continually innovate. Our success will be what we achieve collectively. To accomplish our goals, we have assembled an experienced and highly-skilled group of industry veterans, scientists, clinicians, and leaders from around the world. Our expertise in cancer research and drug discovery serves as the foundation of the organization.
Dr. Kardan is an Associate Professor and chief of Nuclear Medicine and Molecular Imaging at the Baylor College of Medicine. He has an interest in the development and clinical translation of novel, bioimaging markers for the diagnosis and management of various malignancies.
Zeenia is a trained molecular and cell biologist with 11 years of experience in oncology. She has led and overseen ReHeva since its inception to initiating FDA Phase 1 clinical trial. During her graduate and post-doctoral training, Zeenia was awarded several prestigious national and international awards for leadership and research.
Bill is a seasoned entrepreneur with a background in technology and the travel industry. Prior to co-founding ReHeva, Bill was the founding CEO of Silvercar, Inc., a rental car company that was purchased by Audi. He also worked in the airline industry as the CEO of Skybus Airlines and was the former CEO of SystemOne.
More than 30 years of academic research experience in molecular and cell biology. Globally recognized for his research in identifying proteins that cause aging and cancer. Dr. Kaul research has been continuously funded by the National Institute in Japan. Dr. Kaul has served on several boards and advisory panels and actively participates in the peer review process for many national and international funding agencies and scientific journals. With numerous publications and patents, Dr. Kaul has been elected as a Fellow of the National Academy of Sciences, India and Indian Academy of Neuroscience, India. Dr. Kaul services as the chairman of Indian Scientists Association in Japan (ISAJ), Registered Non-Profit Organization (NPO) in Japan.
Dr. Newton has worked for 35 years in the pharmaceutical and biotech life sciences industries. He co-discovered and was the product champion of what is now the largest-selling and most-prescribed cholesterol-reducing drug in the world, atorvastatin (Lipitor®). He is currently Founder, Board Director, and Scientific Advisor at Esperion Therapeutics. Prior to his current responsibilities, Roger was SVP, Pfizer Global R&D, and Director, Esperion Therapeutics, a Pfizer, Inc. company.
Dr. Hoffman has over 35 years of product development experience. She has served as the Director of Extramural Clinical Trials of the Biological Response Modifiers Program at NCI. During her 14-year tenure at the FDA, she formed and chaired an internal FDA Botanical Working Group which developed the Botanical Drug Guidance, which the FDA finalized in 2004.
Joanna brings 15 years of experience in clinical program leadership and management in pharmaceutical and biotechnology research. She has overseen international and national multi-center clinical trials in oncology, neurology, immunology, and diagnostic imaging.
As a company, ReHeva Biosciences checks the box on all the above. But, at several important moments, random good fortune helped propel us forward.
Our story began nearly 20 years ago when a graduate student from India interned at a cutting-edge research laboratory in Japan. The lab was run by a couple, Dr. Renu Wadhwa and Dr. Sunil Kaul, two highly-acclaimed molecular biologists focusing on cancer treatments and gerontology. The student brought with her a small tin of crushed leaves from India and asked for the chance to put them on cancer cells and see if they had any cytotoxic properties. The answer was yes! That small discovery led to 15 years of study, which resulted in the identification of a unique seed line from a common plant that would kill cancer cells and leave healthy cells alone.
Throughout several years, these studies were confirmed in over 20 peer-reviewed publications. Usually, the studies would be the end of the story because trying to bring a new, natural, polymolecular cancer treatment to market was just too improbable. But Dr. Wadhwa and Dr. Kaul’s daughter, Zeenia Kaul, grew up in their research lab and developed a passion for continuing her parents’ work.
Zeenia earned a doctorate in molecular biology from a prestigious laboratory in Sydney, Australia, and completed a fellowship to study cancer research at The Ohio State University. While working on her MBA at the Fisher College of Business, Zeenia took a class in entrepreneurship. Her professor, Bill Diffenderffer, had co-founded several companies, including Skybus Airlines and Silvercar, a car rental company that sold to Audi.
When the semester was over, Bill and Zeenia discussed Zeenia’s parents’ research on a particular cancer treatment. Bill’s wife had just learned her Stage 3C ovarian cancer had reoccurred — and Bill sought to learn more about this groundbreaking work. The more he learned, the more convinced he became that this research could help cancer patients like his wife. There was real possibility.
This was the beginning of ReHeva Biosciences.
